Monitor the company's 10-Q filing for any guidance revisions or disclosures related to the recent board changes. The resignation of two directors may signal governance shifts, but this proxy filing itself is routine.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $86.47entry
- T+1 · 7mo ago −1.27%α −0.79% · $85.37
- T+5 · 7mo ago −3.38%α −3.78% · $83.55
- T+20 · 6mo ago −4.23%α −9.19% · $82.81
- T+60 · 4mo ago +55.06%α +50.28% · $134.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class III directors, ratification of its auditor, and advisory approval of executive compensation. This routine proxy filing follows recent board resignations, suggesting potential governance changes, but the filing itself contains no new material information.
Key Financial Metrics
Key Facts
- Annual shareholder meeting to vote on re-election of three Class III directors: Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr.
- Vote to ratify Ernst & Young LLP as independent auditor.
- Advisory vote to approve compensation of named executive officers.
- Recent context: Two board members resigned effective May 11, 2026, just prior to this proxy filing.
Financial Impact
No material financial figures disclosed in this proxy statement.
Risk Factors
- Potential for governance instability following the resignation of two board members.
- No immediate financial risk indicated by this proxy filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177401 |
| Document: 0001193125-26-177401-index-headers.html | 0001193125-26-177401 |
| Document: 0001193125-26-177401-index.html | 0001193125-26-177401 |
| Document: 0001193125-26-177401.txt | 0001193125-26-177401 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers